Treatment of invasive pulmonary aspergillosis

Keyphrases

• Improved Outcomes 100%
• Amphotericin B 100%
• Surgical Management 100%
• Invasive Pulmonary Aspergillosis 100%
• Voriconazole 100%
• Echinocandins 100%
• Aspergillosis 100%
• Randomized Trial 50%
• Number of Patients 50%
• Invasive Aspergillosis 50%
• Immune Regulation 50%
• Multiple Therapy 50%
• New Antifungal 50%
• Conventional Formulations 50%
• Improved Survival 50%
• Caspofungin 50%
• Posaconazole 50%
• Antifungal Therapy 50%
• Aspergillus Species 50%
• Antifungal Drugs 50%
• Combination Therapy 50%
• Comprehensive Approach 50%
• Echinocandin Antifungal 50%
• Micafungin 50%
• Liposomal Formulation 50%
• Primary Therapy 50%
• Relative Utility 50%
• Amphotericin B Lipid Complex 50%
• Azole Antifungals 50%
• Salvage Therapy 50%

Medicine and Dentistry

• Invasive Aspergillosis 100%
• Antifungal Agent 100%
• Echinocandin 100%
• Surgery 66%
• Combination Therapy 66%
• Amphotericin B 66%
• Voriconazole 66%
• Aspergillosis 66%
• Caspofungin 33%
• Immunomodulation 33%
• Aspergillus 33%
• Antifungal Therapy 33%
• Amphotericin B Lipid Complex 33%
• Pyrrole 33%
• Salvage Therapy 33%
• Posaconazole 33%
• Micafungin 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Invasive Aspergillosis 100%
• Antifungal Agent 100%
• Echinocandin 100%
• Amphotericin B 66%
• Combination Therapy 66%
• Aspergillosis 66%
• Voriconazole 66%
• Aspergillus 33%
• Micafungin 33%
• Antifungal Therapy 33%
• Amphotericin B Lipid Complex 33%
• Pyrrole 33%
• Posaconazole 33%
• Caspofungin 33%